Reduced Use of Maintenance Therapies Among People With Cystic Fibrosis Following Initiation of Elexacaftor/Tezacaftor/Ivacaftor in Australia

• Published in: Clinical therapeutics Vol. 47; no. 9; pp. 813 - 815
• Main Authors: Råket, Hans Kristian, Milder, Tamara, Litchfield, Melisa, Jensen, Camilla Bjørn, Wang, Joanna Nan, Jimenez-Solem, Espen, Petersen, Janne, Pearson, Sallie-Anne, Jaffe, Adam, Falster, Michael O.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2025; Elsevier Limited
• Subjects: Adolescent; Adult; Aminophenols; Anti-Bacterial Agents - therapeutic use; Antibiotics; Australia; Benzodioxoles; Chloride Channel Agonists - therapeutic use; Cystic fibrosis; Cystic Fibrosis - drug therapy; Drug Combinations; Drug Prescriptions - statistics & numerical data; Editing; Endocrine therapy; ETI; Female; Follow-Up Studies; Funding; Gastrointestinal Agents - therapeutic use; Grants; Humans; Indoles; Internal Medicine; Maintenance Chemotherapy - methods; Maintenance Chemotherapy - statistics & numerical data; Maintenance therapies; Male; Medical research; Molecular Targeted Therapy - methods; National; Pharmaceuticals; Pyrazoles; Pyridines; Quinolines; Registry; Respiratory tract; Retrospective Studies; Young Adult; Australia; Cystic fibrosis; Maintenance therapies; ETI; Registry; National; Australia
• ISSN: 0149-2918; 1879-114X; 1879-114X
• DOI: 10.1016/j.clinthera.2025.05.016

Elexacaftor/tezacaftor/ivacaftor (ETI) is an efficacious targeted therapy for cystic fibrosis, but its impact on the use of maintenance therapies has not been assessed in Australia. We performed a retrospective cohort study including individuals with at least 1 ETI dispensing. Quarterly prevalence of airway therapies, antibiotics, and gastrointestinal and endocrine medications was evaluated 24 months before and after ETI initiation. Odds ratios for dispensing were estimated using mixed-effects logistic regression. Airway therapies and oral/inhaled antibiotic use declined after ETI, whereas gastrointestinal and endocrine therapies remained stable. Elexacaftor/tezacaftor/ivacaftor is associated with a reduced treatment burden in cystic fibrosis, supporting broader access.